• Osteosarcoma, Chondrosarcoma, Ewing's sarcoma and other bone cancers

• Treat over 60% of primary malignant bone cancer patients in Taiwan

• International patients seeking cross-border treatment

TVGH's Musculoskeletal Tumor Treatment and Research Center has accumulated 537 osteosarcoma cases since 1984, caring for over 60% of Taiwan's primary malignant bone cancer patients. Guided by the core philosophy of "Seamless Cooperation, Continuous Innovation, and Holistic Care," the center utilizes a multidisciplinary approach integrating orthopedics, pediatrics/oncology, radiology, radiation oncology, nuclear medicine, pathology, and basic research.

After adopting the Mayo Clinic's chemotherapy protocols in 1999, the center improved its five-year survival rate from 48.8% to 70.1%. For patients without pulmonary metastasis treated between 2004 and 2011, this rate reached an outstanding 90.4%. Furthermore, the center maintains a limb-salvage rate exceeding 95%, keeping the amputation rate below 5%.

The team is globally recognized for its surgical innovations. It performed Taiwan's first extracorporeal high-dose irradiation for autograft reconstruction in 1991, now ranking among the world's highest with over 100 cases. It also globally pioneered hemicortical resection and reconstruction, and its liquid nitrogen freezing for autograft devitalization (over 90 cases) surpasses Kanazawa University in volume. Additionally, the team published the world's first clinical evidence that traditional massage (Tui Na) may promote osteosarcoma metastasis, actively driving public health awareness and the continuing education of traditional Chinese medicine practitioners.

• Mayo Clinic chemotherapy protocol adopted (1999): significantly improved survival

• Extracorporeal irradiation autograft reconstruction: Taiwan's first (1991), 100+ cases, globally leading

• Hemicortical resection with biological reconstruction: world-first (presented ISOLS 2009)

• Liquid nitrogen frozen autograft: 90+ cases, surpassing Kanazawa University, Japan

• Biological reconstruction in 89% of cases: saves NHI resources and preserves bone stock

• World-first clinical evidence that manipulation accelerates osteosarcoma metastasis

• Accumulated Cases: A total of 537 osteosarcoma cases (1984-2014), accounting for over 60% of the total cases in Taiwan.

• Reconstruction Volume: Ranks first in Taiwan and among the top globally for allograft or autograft reconstruction cases.

• Cross-Border Medical Care: Served international bone tumor patients (e.g., from the USA, the Philippines, and Southeast Asia).

• Patient Support: Established the Osteosarcoma Caring Association.

• 5-year survival pre/post chemotherapy protocol: 48.8% → 70.1%

• 2004–2011 non-metastatic patient 5-year survival: 90.4%

• 2004–2011 amputation rate: 4.3%; local recurrence rate: 6.8%

• Manipulation vs. non-manipulation local recurrence: 30.6% vs. 6.3% (p=0.011)

• Manipulation vs. non-manipulation 5-year survival: 56.2% vs. 92.0% (p=0.004)

• Over 300 academic papers published by team members

• Biological reconstruction 89%, tumor prosthesis 11% (NHI resource saving)

• Zero-loss intensive patient follow-up system

• Routine dynamic MRI and PET for post-chemotherapy necrosis assessment

• Clinical evidence prompted MOH Traditional Medicine Committee to revise manipulation guidelines

• Health education at 11 schools across Taiwan (2012–2015)

• Ward 93 patient alumni sharing sessions; Make-A-Wish Foundation activities

• ROC Osteosarcoma Caring Association Facebook community

• Holiday ward care events; holistic patient support

• Care package for newly diagnosed patient families

• 50+ invited international lectures/demonstration surgeries since 2006

• European Orthopaedic Society lecture (Madrid, 2010)

• Keynote representing Asian surgeons at Mayo Clinic Franklin Sim retirement symposium (2010)

• Japan Bone and Soft Tissue Tumor Society Annual Keynote (Tokyo, 2012)

• JBJS-Br 2002 cited 121 times; hemicortical resection world-first at ISOLS 2009

• Manipulation research: JBJS-Br 2010, PLOS ONE 2014

• Established Taiwan's highest standard for osteosarcoma surgery and chemotherapy

• Biological reconstruction techniques globally leading, saving NHI resources

• Manipulation-metastasis evidence drove national policy reform and physician re-education

• International patients attracted to TVGH, elevating Taiwan's medical visibility

• ROC Osteosarcoma Caring Association provides comprehensive patient social support